Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy

Invest Ophthalmol Vis Sci. 2009 Aug;50(8):4011-6. doi: 10.1167/iovs.08-3237. Epub 2009 Mar 11.

Abstract

Purpose: To determine whether visual functions are decreased in children with infantile spasms and vigabatrin-attributed retinal toxicity.

Methods: Contrast sensitivity and grating acuity were measured by using sweep visual evoked potential (VEP) testing in 42 children with infantile spasms (mean age, 29.23 +/- 18.31 months). All children had been exposed to vigabatrin (VGB) for a minimum of 1 month. These children were divided into retinal toxicity and no toxicity groupings based on 30-Hz flicker amplitude reductions on the full-field electroretinogram. A multivariate analysis of variance (MANOVA) compared visual functions between children with and without retinal toxicity.

Results: The MANOVA showed that visual function was significantly affected by VGB retinal toxicity. Further univariate analysis revealed that grating acuity was significantly reduced in children with toxicity. No differences in contrast sensitivity were found between children with toxicity and those without.

Conclusions: Reduced visual functions from VGB-attributed retinal toxicity can be detected in children with infantile spasms with the sweep VEP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticonvulsants / adverse effects*
  • Child
  • Child, Preschool
  • Contrast Sensitivity / drug effects
  • Contrast Sensitivity / physiology
  • Evoked Potentials, Visual
  • Female
  • Humans
  • Infant
  • Male
  • Retina / drug effects*
  • Retina / physiopathology
  • Retinal Diseases / chemically induced*
  • Retinal Diseases / physiopathology
  • Spasms, Infantile / drug therapy*
  • Spasms, Infantile / physiopathology
  • Vigabatrin / adverse effects*
  • Vision Disorders / chemically induced*
  • Vision Disorders / physiopathology
  • Visual Acuity / drug effects*
  • Visual Acuity / physiology

Substances

  • Anticonvulsants
  • Vigabatrin

Grants and funding